The largest database of trusted experimental protocols

Amicon ultra 0.5 3k centrifugal filter devices

Manufactured by Merck Group
Sourced in Ireland

The Amicon Ultra-0.5 3K Centrifugal Filter Devices are laboratory equipment used for sample concentration and buffer exchange. They feature a regenerated cellulose membrane with a molecular weight cutoff of 3,000 Daltons. The device is designed to be used with a centrifuge to separate and concentrate macromolecules or other analytes from a sample solution.

Automatically generated - may contain errors

3 protocols using amicon ultra 0.5 3k centrifugal filter devices

1

Determination of α2,3-Sialic Acid PSA

Check if the same lab product or an alternative is used in the 5 most similar protocols
The determination of % α2,3-sialic acid of PSA was performed using a previously published method [9 (link)]. Briefly, ethanolamine 5 M was added to 0.75 mL of each serum sample to a final concentration of 1 M to release the PSA complexed to α1-antichymotrypsin. Total PSA was immunopurified using the Access Hybritech PSA assay Kit (Beckman Coulter, Brea, CA, USA). Amicon Ultra-0.5 3K Centrifugal Filter Devices (Millipore, Cork, Ireland) were used for desalting and concentrating the immunopurified tPSA samples up to a final volume of 40 μL. Samples were then applied to a lectin chromatography using Sambucus nigra (SNA)-agarose lectin (Vector Laboratories, Inc., Burlingame, CA, USA). Eluted unbound and bound chromatographic fractions were collected by centrifugation and quantification of free PSA of these fractions was performed using the Roche ELECSYS platform and used to determine the percentages of fPSA in the unbound fraction, corresponding to α2,3-sialic acid PSA, and in the bound fractions, which correspond to α2,6-sialic acid PSA.
+ Open protocol
+ Expand
2

Isolation and Purification of Serum PSA

Check if the same lab product or an alternative is used in the 5 most similar protocols
After PSA release from ACT, total serum PSA was isolated using the Access Hybritech PSA Assay Kit (Beckman Coulter, Brea, CA, USA). Briefly, a suspension of 100 μl of paramagnetic particles coated with mouse monoclonal anti-PSA (Access Hybritech PSA Assay, Beckman Coulter, Brea, CA, USA) was washed with 500 μl of incubation buffer (50 mM Tris, 150 mM NaCl, pH 7.4, 0.1% Tween-20, 1% BSA) using magnetic separation. The beads were then incubated with 1 ml of neutralized treated serum (containing 750 μl of original serum) for 1h at room temperature (rt) with shaking. Next, the beads were washed with 500 μl of washing buffer (50 mM Tris, 150 mM NaCl, pH 7.4, 1% Triton X-100) using magnetic separation. The immunoadsorbed PSA was eluted in three steps using 100 μl of Gentle Ag/Ab Elution Buffer, pH 6.6 (Thermo Scientific, Rockford, IL, USA) for 30min each. The final elution volume was of 300 μl. Samples were desalted and concentrated to a final volume of 40 μl using Amicon Ultra-0.5 3K Centrifugal Filter Devices (Millipore, Cork, IRL), which had been previously pre-treated with 5% Brij-35 (Sigma-Aldrich, Germany) and used for sample desalting according to the manufacturer's instructions.
+ Open protocol
+ Expand
3

Separation of PSA Glycoforms by SNA Chromatography

Check if the same lab product or an alternative is used in the 5 most similar protocols
Separation of blood serum α2,3 and α2,6-SA PSA glycoforms was performed using SNA chromatography as described previously27 (link). Briefly, 0.75 ml of serum samples were treated with 1 M ethanolamine to release the PSA complexed to ACT. The tPSA was immunopurified using paramagnetic particles coated with mouse monoclonal anti-PSA antibody from Access Hybritech PSA assay Kit (Beckman Coulter, Brea, CA, USA), and then desalted and concentrated up to a final volume of 40 µl with Amicon Ultra-0.5–3 K Centrifugal Filter Devices (Millipore, Cork, Ireland). Concentrated samples were processed by lectin affinity chromatography using SNA-agarose lectin (Vector Laboratories, Inc., Burlingame, CA, USA). Eluted unbound and bound fractions were collected by centrifugation and the fPSA of these fractions was quantified by Roche ELECSYS platform to determine the relative percentages of fPSA in the unbound (corresponding to PSA glycoforms containing α2,3-SA), and the bound fraction (containing α2,6-SA PSA glycoforms).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!